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ABSTRACT

The innate immune system is many organisms first line of defense against
pathogenic insult or tissue damage [1]. This defense strategy is intent on restoring
homeostasis upon perturbation. Upon activation of the innate immune system in humans,
an oligomeric protein complex termed the “Inflammasome” forms in myeloid cells [2].
The canonical output of activation of any subset of inflammasome is Caspase-1-mediated
secretion of pro-inflammatory cytokines IL1β and IL18 [3, 4]. Chronic or uncontrolled
inflammasome activation is at the core of myriad economically burdening diseases [5-8].
In many of these diseases, endogenous factors chronically engage the innate immune
system. To study these diseases in in vivo, over time as they progress, in a transgenic
organism will segue into the development of next generation therapeutics. In this study
we sought to utilize a modified Firefly Luciferase (pGLO) construct to measure Caspase1, and thus, inflammasome activity. pGLO has been engineered to be catalytically
activated in response to targeted cleavage by a protease [9]. We report that insertion of a
short peptide sequence targeted by Caspase-1 into the linker region of a circularly
permuted Firefly Luciferase (pGLO) has allowed us to quantitatively assess the level of
inflammasome activation in live cells. A successful in vitro experiment demonstrating
sensitive and specific quantification of Caspase-1 activity should lead to an in vivo mouse
model for the study of inflammatory disease.

x

CHAPTER ONE
INTRODUCTION
Statement of the Problem
Auto-Inflammatory diseases (AID), Metabolic Syndromes including Obesity and Type 2
Diabetes, and more recently Neurodegenerative Diseases all share a common thread of
chronic dysregulation of inflammation [4, 5, 10, 11]. Alzheimer’s disease is known to
afflict approximately 6% of people over the age of 65, a growing concern as longevity
steadily increases [12]. A constant amongst these disorders and disease states is a
disruption in homeostatic control of the processing and secretion of IL1β, an
inflammatory cytokine involved in innate immunity [4, 13]. The generalized
“Inflammasome” refers to a collection of related oligomeric platforms for activating
Caspase-1 [2, 3, 14]. Caspase-1 can in turn process pro-inflammatory cytokines such as
pro-IL1β into mature cytokines to coordinate the innate immune response. Studies
suggest that inflammasomes normally form in response to exogenous pathogen associated
molecular patterns (PAMPs), or more simply conserved molecular motifs recognized by a
Pattern Recognition Receptor (PRR) [15]. Endogenous “pathogens” in the form of
Danger Associated Molecular Patterns (DAMP’s) can activate Pattern Recognition
Receptors in chronic disease states [13]. Loss of regulation of the formation, activation,
or resolution of the inflammasome through pathways only beginning to be elucidated will
be targets of future therapeutic intervention.
1
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Quantitatively measuring the efficacy of therapeutics via high throughput screens
(HTS) or in vivo animal model will greatly increase the number of “hits” to be further
advanced into clinical trials. Presently, inflammasome activity can be quantified in the
research laboratory by assays such as Western blotting, ELISA, or FLICA (Fluorescent
Labeled Inhibitor of Caspases) [16] [17, 18]. The cellular pathway classically targeted in
developing inflammasome assays is the aforementioned proteolytic processing of ProIL1β by active Caspase-1 [18]. Thus, measuring levels of mature, secreted IL1β protein
in a sample preparation via ELISA is a go-to method of quantifying inflammasome
activity in vitro [17] [18] .
Fluorescent proteins conjugated to short peptide sequences, which fluoresce upon
cleavage by proteases such as Caspase-1 (FLICA), present an alternative to ELISA.
Similar to ELISA and Western blotting, these assays only work in vitro and display a
narrow dynamic range in sensitivity [19]. Researchers have long known the strength of
luminescence assays is in their broad dynamic range and minimal levels of background
noise when compared to fluorescence assays. [20]. This thesis describes the development
of a novel assay able to quantify inflammasome activity utilizing a genetically encoded
Firefly Luciferase derived protein (pGLO). The ability to sensitively assess
inflammasome activity, first in a high-throughput in vitro setting and subsequently in an
in vivo animal model utilizing a dual purposed assay will be possible with the advances
documented in this thesis.
. The potential to assess inflammasome activity in vivo with this technique makes
it a powerful alternative to present assays. The literature has suggested that discrepancies
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exist between Caspase substrates in vitro and in vivo affirming the need for an in vivo
inflammasome and thus Caspase-1 assay [21]. Firefly Luciferase (FFL) derived proteins
have been engineered to serve as bioluminescence sensors for a variety of intracellular
and extracellular interactions. Structurally, Firefly Luciferases (FFL) uniquely possess a
linker region between an N and C terminal domain as compared to other bioluminescent
proteins [22]. This presents the possibility of forward genetic engineering modifications
to alter FFL functionality in response to various stimuli.
It has been demonstrated that modifications to the unstructured linker region of a
circularly permuted Firefly Luciferase (pGLO) can result in the generation of a sensor for
cAMP, rapamycin and protease cleavage [19, 23, 24]. Many proteins, including the
entire human Caspase family are known to cleave substrates in an unstructured extended
loop conformation [25]. We hypothesize that the insertion of a short amino acid
sequence cleaved by active Caspase-1 into the linker region of a circularly permuted
Firefly Luciferase (pGLO) will result in a luminescence based inflammasome sensor.
With the drawbacks of current inflammatory assays in mind, the objective was to
develop a novel, genetically encoded bioluminescence sensor for inflammasome activity.
This technology is broadly applicable to the study of established and emerging diseases
with any component of inflammasome activation. Furthermore, this study describes the
use of a technology (pGLO) with the potential to measure the activity of any protease.
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Inflammation
Inflammation is a highly coordinated response to stimuli in the form of exogenous
pathogen, physical trauma, or endogenous factors [1, 13]. The inflammatory response
occurs at the level of tissue and is mediated by resident immune cells and migratory cells.
Tissue resident mast cells and phagocytes; which include dendritic cells and macrophages
are responsible for the initial response (Figure 1). These cells can secrete chemokines
and cytokines into the environment to coordinate the recruitment of circulating and
subsequently infiltrating leukocytes (Figure 1). Dendritic cells secrete IL-12 or
Interferon-Alpha in addition to presenting antigen to T-cells; this links the innate and
adaptive immune responses [28]. Macrophages secrete over 9 Interleukins, TNFα, and
CXCL’s mainly involved in mediating migration and entry of neutrophils, basophils,
eosinophils in addition to lymphocytes; another link between innate and adaptive immune
responses [29].
The coordinated inflammatory response consists of two components. The innate
immune system initiates the broad response to a diverse range of stimuli with the intent
of restoring homeostasis. If this is insufficient in resolving the insult, the higher order
adaptive immune response unique to vertebrates is activated [30]. This thesis describes
the development of a sensor for the inflammasome and thus need not focus on the latter
adaptive immune response.
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Innate Immune System:
Innate Immunity begins with the epithelial layer of tissue. Once the epithelial
layer of tissue is breached, then the innate immune system is initiated [30]. Conserved
pathogenic motifs (PAMP’s) can be recognized by membrane bound TLR’s and large
families of intracellular receptors of mast cells and macrophages [1] (Figure 1).
Membrane bound receptors typically belong to the family of Toll-Like Receptors
(TLR’s) containing a Leucine Rich Repeat Domain (LRR) are the first to be engaged [15,
31]. Intracellular receptors, which may be membrane bound in some cases include the
NLR family, IPAF/NAIP, and NOD in addition to newly discovered less characterized
receptors such as Interferon-Inducible Protein, AIM2 [2, 15]. The NLR family of
receptors, the focus of this thesis, may be engaged by a swathe of stimuli. (Figure 2 and
Figure 3). These receptors are thought of as separate signaling entities, the former TLR
engagement as “Step 1” and the latter NLR receptor engagement as “Step 2.” Upon
successful engagement of both steps the inflammasome is activated [14].
Step 1 “Priming” involves the engagement of membrane bound TLR’s by a
PAMP or DAMP (Figure 3). Priming is important for the upregulation of NFκBcontrolled expression of pro-inflammatory genes. The NFκB-induced increase in copy
number of proIL1β and proIL18 transcripts has been documented and plays a role in Step
2 [13]. Step 2 is the activation of the inflammasome via signaling through an NLR
family, IPAF/NAIP, or NOD receptor protein. This two- step process has been conserved
to avoid unnecessary inflammasome activation, which is thought to be a detriment to
health [14].

6

Figure 1: Innate Immune Response to generalized bacterial infection
1. Tissue Resident cells are the first responders and secrete chemokines
and cytokines leading to (2)
2. Leukocytes migrate to the site of infection

Table 1: Cells of the Innate Immune Response
(table adopted from [Boundless. “Pathogen Recognition.” Boundless Biology. Boundless,
14 Sept. 2015.)]
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PAMPS/DAMPS
PAMP’s/DAMP’s can activate different inflammasome subsets by signaling
through both a TLR and subsequently the Leucine Rich Repeat (LRR) domain of a
receptor (Figure 2-3). The LRR motif has been demonstrated to be involved in proteinprotein interactions and has various mutations in TLR’s allowing it them to recognize a
diverse array of pathogens [31]. It is unclear at this point if the ligand activating the LRR
is the PAMP/DAMP itself [14] [32]. Some suspect that unidentified intermediates may
serve as the receptor for a PAMP/DAMP and signal through the LRR of the NLR
inflammasome proteins. PAMP’s are typically thought of as conserved motifs of DNA,
RNA, or protein derived from a viral or bacterial infection recognized by a family of
receptors yet to be described (Figure 2). Interestingly, the specific bacterial DNA motif
thought to be recognized as a PAMP consists of a CpG motif comprising the dinucleotide
CpG bordered by an upstream 5’ purine pair and a downstream 3’ purine pair [33].
Alternatively, and most important for this body of work, DAMP’s are derived from the
environment and have well-characterized disease associations listed and cited in Table 2.
As indicated, Table 2 illustrates disease associations for the best characterized NLRP3
inflammasome. Although, there may be a degree of cross-talk amongst inflammasome
activation pathways leading to varying levels of activation of multiple species of
inflammasome.

8

Figure 2: DAMP’S and PAMP’s lead to Inflammasome Activation
(Reproduced with permission of Margaret Bradley)
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The Inflammasome
In 2002, Martinon et al, proposed the existence of a large oligomeric complex of
proteins with the function to mediate immunity [3]. This is in light of the previous
suggestion of a complex formed in cells on the pathway to apoptosis termed the
“Apoptosome” [34]. This proposition has been affirmed with the discovery and ongoing
discoveries of multiple subsets of inflammasomes [5, 13]. Inflammasomes have been
shown to form in cells of the myeloid lineage, microglia, neurons, astrocytes, and
keratinocytes [10, 14, 35] [14].
Upon the reception and activation of a primarily intracellular PRR, additional
inflammasome components are recruited to the receptor. This is of course, preceded by
Step 1, the priming step via TLR engagement by the PAMP or DAMP. Figure 5
illustrates the general schematic and components of the best characterized
inflammasomes. The common features to all inflammasomes is a receptor, sometimes an
adaptor protein, ASC, and always Pro-Caspase-1 [36]. However, research suggests that
Pro-Caspase-5 or perhaps Pro-Caspase-4 may take the place of Pro-Caspase-1 and play a
role in active inflammasomes signaling [3]. The inflammasome components are thought
to be self-oligomerizing [2]. It is known that assembly of the inflammasome is
maintained through homotypic protein interactions often involving the adaptor protein
ASC. CARD-CARD and PYRIN-PYRIN domain interactions of two proteins
constituting the various species of inflammasomes hold the complex together [2]. It is
speculated that the NLR receptor’s NACHT domain mediating receptor oligomerization
is critical for formation of the inflammasome complex [37].
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A diagram of the most extensively characterized inflammasome, NLRP3 can be
seen in Figure 3. Presently it is unclear whether Pro-Caspase-1 or the Leucine Rich
Repeat, (LRR) portion of an NLR lies on the inner portion of the complex [15]. The
spiral-like oligomeric NLRP3 inflammasome complex is speculated to contain six or
seven associated Receptor-Adaptor-Pro-Caspase-1 complexes [2] (Figure 4). As of now,
it is unclear whether or not “heterocomplexes” of perhaps, an NLRP1 and NLRP3
inflammasome are formed [38] [39].
The common feature to all known inflammasome subsets is the processing of ProCaspase-1 into mature Caspase-1. Caspase-1 is an inflammatory protease classically
known to cleave proIL1β and proIL18 into their mature forms. Caspase-1 has 50-100
targets in humans with some overlap with proteins involved in apoptosis such as
Caspase-7 [32]. Some have referred to the processes mediated by Caspase-1 as
“pyroptosis,” a form of programmed cell death. Pyroptosis involves DNA cleavage, pore
formation in the cell membrane, release of pro-inflammatory cytokines and subsequent
cell death through swelling and lysis [40]. The pyroptotic process functions to limit the
spread of a bacterial or viral infection [13].

11

ROS

Figure 3: Two Step Process to NLRP3 Inflammasome Activation
Step 1: Priming a PAMP or DAMP described in Table 5 induces NFκB
transcription of pro-inflammatory cytokines. Step 2: NLRP3 engagement 1:
Endocytosis of a PAMP/DAMP leads to lysosomal leakage of Cathepsin B or
ROS. 2: K+ efflux triggers opening of Pannexin-1 allowing direct entry of
PAMP/DAMP. 3: Production of generalized ROS via PAMP/DAMP NLRP3
agonism activates the NLRP3 Inflammasome. (diagram adopted from [The
Inflammasomes])

Figure 4: The Spiral Inflammasome Formation
(Permission granted through Rightslink®, (Klareskog and Hansson, 2011)
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Figure 5: NLR Inflammasome Component Proteins
Abbreviations: PYRIN – Pyrin Domain, CARD – Caspase Activation and
Recruitment Domain, LRR – Leucine Rich Repeat, FIIND – Function to Find
Domain, p20 and p10 – large and small subunit of pro-Caspase-1, NACHT –
Neuronal Apoptosis Inhibitor Protein
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Regulation
The inflammasome and its immediate downstream processes are subject to
transcriptional and post-translational regulation. The availability of the pro-IL1β and
pro-IL18 are under tight regulation via NFκB signaling [15]. Whereas the expression of
the adaptor ASC and Pro-Caspase-1 are found in many cell types; expression levels of the
aforementioned PRR’s are subject to variable cell type-specific expression patterns [4].
Factors such as the compartmental trafficking of inflammasome constituents, splices
variants, microRNA, or existence of inhibitors can contribute to inflammasome
regulation [41-43]. The inflammasome and IL1β protein are similar in that they are
subject to regulation through binding to decoy, dominant negative proteins [44] [41].

POP’s
Little is known about inflammasome constituent trafficking or splice variants –
particularly of the adaptor ASC [43]. However, a family of proteins referred to as PyrinOnly-Proteins (POP’s) , and CARD-Only-Proteins (COP’s) have been documented to
regulate inflammasome activity through direct homotypic interactions [45]. POP’s are
known to bind to the Pyrin domains of some NLR’s and could perhaps bind to the Pyrin
domain of the adaptor, ASC [41]. There are 2 POP’s encoded in the human genome
referred to as POP1 and POP2 with a very recently discovered POP3 [46]. A PAMP in
the form of poxvirus have evolved an ability to suppress the host immune response in
humans in response to their infection. This unique evolutionary strategy to evade innate
immune surveillance is partially attributed to the presence of virally encoded POP’s [47].
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COP’s
In humans COP’s include Iceberg, COP1, INCA, Caspse-12 short (not present in
some humans), and NOD2S [48]. Of the 5-protein family of COP’s, a sequence
similarity of between 53% to 92% with the CARD domain of Caspase-1 has been
documented [49]. Genomically, COP’s reside near the Inflammatory Caspases 1, 4, and
5 on human chromosome region 11q22.3 indicating evolution via gene duplication [49].

Adaptive Immune Regulation
Antigen-Presenting Cells (APC’s) such as dendritic cells and macrophages also
(Figure 1) phagocytose pathogens; which they display on their surface to migratory Tlymphocytes. T-lymphocytes are a broad class of cells consisting of Helper, Cytotoxic,
Memory, Suppressor, and Natural Killer the function of which is related to their name
and need not be detailed. As mentioned, APC mediated presentation of pathogenic
antigen to T-Cells bridges the gap of innate and adaptive immunity. Type 1 Interferons a
commonly utilized therapy in inflammatory disease, secreted by pathogen-infected cells
play a role in decreasing inflammasome activity. ProIL1 protein can be decreased and
Caspase-1 activation attenuated in Interferon-β-treated macrophages [50].
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NLRP3 Inflammasome
As of late 2013, there were 274 NLRP3 inflammasome (NLRP3IN) related
publications; by far the most extensively characterized subset of inflammasome.
NLRP3IN is made up of NLRP3 receptor, ASC adaptor, and Pro-Caspase-1 [35]. The
NLRP3 inflammasome was originally found to be activated by bacterial and viral toxins
(PAMP’s) such as Influenza, Sendai Virus, Listeria Moncytogenes Staph Aureus, and
bacterial pore-forming toxins including Nigericin. Around 2008, researchers began to
study the endogenous DAMP’s found to chronically activate the NLRP3 inflammasome
leading to the diseases found in (Table 2). There are 3 models of NLRP3 inflammasome
activation proposed and thought to be the most substantiated by existing evidence
(Figure 3) [2, 13].
1. Endocytosis of PAMP’s/DAMPS’s leading to leakage of lysosomal proteases
such as Cathepsin B into the cytosol [51] [52].
2. K+ Efflux Stimulation of P2X7 or P2X4 potassium (K+) ion channels via
extracellular ATP. This triggers formation of large integral plasma membrane
complexes-pannexins, which allow PAMP or DAMP entry and NLRP3
receptor engagement. Potassium efflux is highly implicated in this process
with numerous studies aimed at elucidating the effects of varying intra versus
extracellular potassium [53] [54].
3. DAMP/PAMP induced increase in ROS. The ROS sensitive ThioredoxinInteracting Protein is a ligand for NLRP3 receptor and is thought to be
involved. [55].
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Research is beginning to implicate additional pathways of involvement with
NLRP3 activation (Figure 6). These pathways are supported by minimal data but will
serve as guidance for future directions in elucidating activation and regulation of all
subsets of inflammasome. The utility of an inflammasome Sensor in further elucidating
these pathways is significant.

Figure 6: NLRP3 Inflammasome Regulation and Activation (permission
granted through Rightslink®, diagram adopted from [56]
Green Arrow indicates Activation while Red indicates inhibition.
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Additional NLRP3 activators
The role of additional molecular regulators of NLRP3 receptor activation and the
formation of a complete NLRP3 inflammasome has received much attention.

NLRP3

mRNA is under control of NFκB and microRNA; as a result levels of the protein are
variable amongst innate immune system cell types [57]. NLRP3 has been found to be
ubiquitinated in a basal state; deubiquitination and activation were instigated by a
priming signal. [58]. In mice, signaling through TLR4 relays through MyD88 coupled
with mitochondrial ROS leading to deubiquitination of resting NLRP3 receptors [58]. It
is speculated that multiple residues of NLRP3 are poly-ubiquitinated in a basal state and
separate de-ubiquitinating enzymes activated by priming or activating signal lead to
deubiquitination and activation. [58]. Protein Kinase R (PKR) directly interacts with
NLRP3 and can regulate multiple inflammasome subsets [59]. A swathe of DAMP’s
including MSU, ATP, dsRNA, anthrax, and rotenone were able to induce a dampened
inflammasome response when PKR is inhibited by genetic ablation or drug [59]. NLRP3
inhibition is thought to be mediated by LRR domains in addition to SGT1-HSP90
Chaperon complexes [60].
Reactive Oxygen Species (ROS) have been shown to play conflicting roles in
NLRP3 inflammasome activation. Thioredoxin Interacting Protein (TXNIP) dissociates
from Thioredoxin upon sensing ROS and like the above-mentioned regulators can bind to
and activate NLRP3 [13]. The mitochondrial oxidative stress pathway has been
implicated through interactions with autophagy, Ca++ signaling, and ROS [61].
Autophagy, an intracellular degradation pathway, is responsible for digesting damaged
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mitochondria. If this pathway is perturbed, then the effects of damaged mitochondria
such as increased ROS and leakage of oxidized mtDNA induced by a PAMP/DAMP can
lead to NLRP3 activation [62]. Strangely, Superoxide dismutase deficient-macrophages
have elevated ROS, but display stunted inflammasome activity as shown by decreased
cytokine production [63]. In these macrophages, Cys397 and Cys362 of Caspase-1 were
found to be reversibly glutathionylated [63].

NLRP3 related Inflammatory Diseases
IL1β and IL18 have been shown to be elevated in localized tissue or systemically
throughout the body in an increasing number of diseases (Table 2). Drugs such as
Kineret® (Anakinra) have been developed to broadly target the elevation of IL1β through
IL1 receptor antagonism. Future therapeutics will certainly offer more refined control of
subsets of inflammasome rather than blanket modulation of the IL1R and in turn, IL1β.
Before these treatments make it to clinical trial, testing for safety and efficacy in an in
vivo transgenic organism will decrease the cost of advancing the development of a
therapeutic.
Cryopyrin-Associated Periodic Syndromes (CAPS)
Many rare auto-inflammatory diseases fall under a generalized category of:
Cryopyrin-Associated Periodic Syndrome (CAPS). These are nearly all characterized by
a mutated NLRP3 gene, increased NLRP3 inflammasome activity, and elevated IL1β
secretion. These orphan diseases are responsive to treatment with an Anakinra ®, an
antagonist to the IL-1 receptor [5].
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Neurodegenerative Disease
Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis
(ALS) all share a component of IL1β elevation in the brain.[11, 64, 65] The protein
aggregates formed by Amyloid-β (aβ), α-synuclein, and SOD1 respectively are all
thought to trigger activation of the NLRP3 or NLRP1 inflammasome as DAMP’s.
Microglia, thought of as very similar to myeloid cells are frequently found aggregated
around these proteinaceous deposits/inclusion in Alzheimer’s and Parkinson’s disease.
Microglia are essential for the inflammatory response in the CNS; however, neurons have
been demonstrated to form NLRP1 inflammasomes as well. [4]
Metabolic Syndrome
The NLRP3 inflammasome has been demonstrated to be elevated in human
individuals and mice fed a high-fat diet [13]. Broad spectrum IL1 receptor inhibition is
being studied in clinical trials as a method of treating Type 2 Diabetes mediated by islet
amyloid polypeptide (IAPP) activation of macrophages. [66-69]
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Table 2: NLRP3 Inflammasome Associated Diseases
Disease
Gout
Metabolic
Syndromes
Allergy
Atherosclerosis

PAMP/DAMP
Uric Acid Crystals

Cytokine

Reference

IL1β

7

Ceramide, Free Fatty Acids
IL1β
Islet Amyloid Polypeptide (IAPP) IL18
Hyaluronan, Dust Mites
IL1β

5, 66-69
4,5

Cholesterol, Oxidized LDL

IL18

13, 35

Parkinson's

α-Synuclein

IL1β

8,65

Alzheimer's

Amyloid-β

IL1β

11,35,65

Super Oxide Dismutase 1

IL1β

13

ALS

(Permission granted through Rightslink®, table adopted from [5].

21
Caspases
There are 11 Cysteine-Aspartate-Proteases in humans all of which normally exist
in a pro-form (Figure 7) as approximately 30 to 53 kilodalton (kD) zymogens. The 11
human caspases are further classified into 3 distinct groups based on their functions,
enzymatic preferences, and sequence homology. The two cleaved subunits from one procaspase can interact with two cleaved subunits from an identical pro-caspase to form an
active tetrameric, mature caspase. It is currently unknown if p20 or p10 subunit from
different pro-caspases can form chimeric, mature caspases. Caspases always cleave
immediately after an aspartic acid residue in the P1 position. The 3 groups of caspases
prefer different amino acid residues at other positions of their targets. The 3 positions
preceding the P1 position are P2 preceded by P3 and then P4. The positions following P1
are typically referred to as, respectively, P1’, P2’, P3’ etc. The P4 position is thought to
be most important with regards to enzymatic specificity of caspase for their substrates;
with the P2 and P3 positions playing much lesser roles [70].
In Figure 7 one can see the similarities in the catalytic active site of a sampling of
caspases from each group. Group 1 is Inflammation related, Group 2 is Apoptosis
related, and Group 3 consists of upstream initiator caspases. Through generation of
substrate libraries, the scientific literature has documented ideal, consensus cleavage
sequences targeted by each caspase or group of caspases (Table 4). The Inflammatory
caspases of Group 1 prefer the bulky hydrophobic amino acid tryptophan in the P4
position. The Apoptotic caspases of Group 2 prefer the more compact aspartate in P4
thus allowing for selectivity in this position due to exclusion of bulky amino acids.
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Figure 7: Caspase zymogen and 3-Dimensional structure

(Permission granted through Rightslink®, [71]

Table 3: Caspase Consensus Sequences
Protein

Group

Optimal Sequence

Caspase-1
Caspase-4
Caspase-5

I
I
I

WEHD
(W/L)EHD
(W/L)EHD

Caspase-3
Caspase-7
Caspase-2

II
II
II

DEVD
DEVD
DEHD

Caspase-6
III
VEHD
Caspase-8
III
LETD
Caspsae-9
III
LEHD
(Adopted from a table in [70]
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Caspase 1
Caspase 1, previously known as Interleukin-1β Converting Enzyme (ICE) is first
synthesized as a 45kD pro-enzyme zymogen. Pro-Caspase-1 contains three distinct
domains: CARD, p20, and p10 subunit domain. The Caspase-Activation and
Recruitment Domain (CARD) is responsible for a homotypic interaction with a CARD
domain of the adaptor ASC in the NLRP3 inflammasome. Upon activation of the
inflammasome the p20 and p10 subunits are auto-proteolytically cleaved. Two p20 and
two p10 subunits can associate to form a heterotetrameric active Caspase 1 enzyme.
The canonical output of Caspase 1 activation is the proteolytic processing of ProIL1β and Pro-IL18 into their mature forms for secretion from innate immune cells of the
myeloid lineage. This is of course proving to be true for other cell types more recently.
Pro-IL1β and pro-IL18 are the only Caspase-1 substrates found to be cleaved both in vivo
and in vitro under pathological or physiological conditions [72].

Luciferase
“Luciferase” is a generic term referring to a class of enzymes with the function to
catalyze a bioluminescent, light producing reaction in a variety of organisms. Reactions
that catalyze bioluminescence with a “luciferase” type enzyme have evolved through
convergent evolutions up to 30 times in both prokaryotes and eukaryotes [73]. The
luciferase proteins receiving the most attention in biomedical research are Firefly
Luciferase (Photinus pyralis), Renilla Luciferase (Renilla Reniformis), and Gaussia
Luciferase (Gaussia Princeps) [74, 75]. Generally speaking, the catalytic mechanism in
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producing light by all forms of luciferase involves an oxidation reaction of a type of
luciferin molecule, resulting in the emission of a photon. Luciferases utilize a variety of
cofactors in their light producing reactions including ATP, Ca++, Riboflavin Phosphate,
or O2. As the molecular biology of Luciferase enzymes was beginning to be understood
the potential to utilize these enzymes as reporters of fluctuations in cellular activity came
to light.
The potential application of luciferase proteins in assays of genetic activity
continues to be realized and advanced. In the beginning, people would place a luciferase
gene downstream or otherwise under control of a candidate promoter and probe for the
strength of the promoter. One could analyze normal or disease associated mutant
promoter controlled gene expression via a downstream luciferase reporter. Most
importantly, high-throughput screens (HTS) of candidate drug compounds could now be
performed for targets of G-Protein Coupled Receptors (GPCR’s) [20]. An example of
this involves cloning a luciferase gene downstream and under control of a cAMP
response element. Ultimately, a G-Protein Receptor activating drug will signal and
converge on the increase in cAMP, it’s binding to the CRE. The effect of the drug on
signaling via this pathway or perhaps many others can be measured by bioluminescence
proteins under genetic control CRE or another element.
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Firefly Luciferase
Firefly Luciferase (FFL) is a 61kD monomeric enzyme with two distinct domains
located towards the N and C termini separated by a linker [22]. Functionally, this linker
region is thought to act as a molecular hinge between the two subunits. Catalytic activity
is highest when the hinge motion is exercised through a “closed” conformation between
the N and C terminal domains[22]. Firefly luciferase has continued to be utilized
extensively as a reporter of intracellular activity since it was first cloned in 1985 [76]. In
fact, as of 2010 ~21 percent of greater than 2000 assays listed on the PubChem database
were bioluminescence based. [74] Firefly luciferase is ubiquitously used in research and
development in the Dual Luciferase Assay popularized by Promega®. At the molecular
level, Firefly Luciferase is normally free from post-translational modifications making it
well-suited for a eukaryotic cellular environment of protein modifying enzymes. As the
potential uses for FFL in HTS was continuing to be illustrated, people took considerable
interest in modifying the protein through molecular biology for various applications.
Researchers took to adding various intracellular localization sequences, degradation
sequences, and even single nucleotide polymorphisms (SNP’s) to increase the catalytic
efficiency of the enzyme [20, 74, 77].
Circularly Permutated Firefly Luciferase
Circular permutation of a protein is an alteration in the spatial order of amino
acids in the overall primary peptide sequence. The protein may have a similar tertiary
structure to the original protein yet the primary sequence is rearranged (Figure 8, Left –
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Primary, Figure 8, Right– Tertiary). Circularly permutated proteins can be
advantageous for researchers due to manipulation of factors such as thermostability,
catalytic efficiency, and resistance to proteolytic processing [20, 77]. Through directed
evolution by generation of large DNA libraries researchers can generate highly
functional, novel, circularly permutated proteins [78, 79].
The early success of circularly permutated fluorescence based biosensors for
intracellular events as early as 1999 may have corroborated the need for investment in the
technology [78]. Promega® Corporation set out in the mid 2000’s to evolve a circularly
permutated Firefly Luciferase capable of monitoring intracellular events in real-time.
This concept may have been influenced by the success of split luciferase technology
which results in a fragmented protein engineered to reconstitute activity in response to an
intracellular event [80] [81].
Directed evolution of a 544-AA protein began with the unstructured linker region
between the N and C Terminus. The isolated mechanism of the N and C-terminal
domains enclosing on the catalytic active site has been targeted in the design of cpLUC
[22]. The design strategy involved the restriction of this enclosure mechanism via a
modified hinge region [19]. Binkowski et al created a library of potential modified
firefly luciferases tolerant of circular permutation, which they could test for functionality.
The first utility of cpLUC was discovered in sensing the activity of cAMP,
rapamycin, and additional proteases. Researchers at the Promega® took to engineering
restriction sites into the linker region of pGLO to allow for cut and paste cloning of short
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amino acid (AA) sequences. First through overexpression studies, Promega® researchers
tested the hypothesis that insertion of an AA sequence into the linker of cpLUC could
lead to a sensor for protease activity. The hypothesis has proven true for developing
pGLO based sensors of the proteases Caspase 3/7, Granzyme B, MERS CoV, TeV, [9,
19, 23, 24, 27, 82-84]

Figure 8: Molecular Mechanism of pGLO
(Reproduced with permission of Brock Binkowski, Promega® Corporation)
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Hypotheses
We hypothesize that insertion of a Caspase 1 target sequence from a known substrate into
a circularly permuted form of Firefly Luciferase (pGLO) will generate a sensitive and
specific sensor for inflammasome activation

Specific Aim 1. To determine if we can detect Caspase-1 activation with our pGLO
sensor construct
A. Clone our Caspase 1 proteolytic target sequence into the pGLO modified
luciferase sensor
B. Overexpress two out of three components of the NLRP3 inflammasome and
measure bioluminescence from live cells
C. Create a stable cell line and measure bioluminescence in a physiologically
relevant setting

CHAPTER TWO
MATERIALS AND METHODS
Cell Lines and Reagents
The human embryonic kidney cell line HEK293T and the human cervical
epithelial cell line HeLa were obtained from the American Type Culture Collection
(ATCC).

Cell Culture
HEK293T cells and HeLa cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) media, supplemented with 10% fetal bovine serum (FBS), 100 IU/ml
penicillin, 100 μg/ml streptomycin, 10 μg/mL ciprofloxacin. Cells were maintained in a
37° incubator with 5% CO2.

Molecular Cloning
The pGloSensor-30F DEVDG (pGLO) construct was a kind gift from Promega®
Corporation. Oligonucleotides for insertion into pGLO construct can be referenced in
Tables 3 and Table 4. Primers were codon optimized for non-degeneracy via the
reverse translation tool at www.bioinformatics.org. The pGLO construct was restriction
digested overnight with BamH1 and Hind3 restriction enzymes in NEB buffer 3.1 both
purchased from (New England Biolabs® Inc.) to reveal 2 overhang sites. Forward and
Reverse primers from Table 3 and Table 4 were annealed via a PCR thermal cycler and
ligated into the double digested pGLO construct using a Quick Ligation™ Kit (New
England Biolabs ® Inc.) Ligated constructs were transformed overnight with NEB 529
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alpha Competent E.coli (New England Biolabs® Inc) and selected for based on
ampicillin resistance. Colonies were picked, grown up, and miniprepped (QIAprep Spin
Miniprep Kit, Qiagen®) following the manufacturer’s instructions.

Diagnostic Restriction Digest
The pGLO sensor constructs in Table 3 and Table 4 were double digested
overnight with SnaBI and HindIII restriction enzymes in NEB buffer 2.1 both purchased
from (New England Biolabs® Inc.) The overnight digestion was mixed with 6x Loading
Dye (New England Biolabs® Inc.) and 20 µl was loaded into each lane of a 1% agarose
gel. 6 µl of Benchtop 1kB DNA Ladder (Promega®) was loaded into the first lane of
each gel to visualize the size of each band. Gel electrophoresis was performed for ~45
minutes at 70V in 1X TAE buffer. Gels were visualized with a Chemi-Doc XRS+
(BioRad, Inc) using Image Lab Software. Putative DNA sequences for each sensor
construct were digested utilizing the computer software program ApE (A Plasmid Editor)
to determine predicted band size. Restriction digested clones can be referred to in
(Figures 10-16) of the Results Section
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Table 4: Primers for insertion into linker region of pGLO-Caspase 1 targets
Sequence
pGLC7
pGL18
pGL1Beta
pGLPA
pGLC75
pGLWE

Primers 5' to 3' Fwd and Rev
gatccATTCAGGCGGATAGCGGCCCGATTGGa
agcttCCAATCGGGCCGCTATCCGCCTGAATg
gatccCTGGAAAGCGATTATTTTGGCAAAGGa
agctTCCTTTGCCAAAATAATCGCTTTCCAGg
gatccTATGTGCATGATGCGCCGGTGCGCgga
agctTCCGCGCACCGGCGCATCATGCACATAg
gatccCTGCATACCGATAGCCGCAAAGATGGa
agctTCCATCTTTGCGGCTATCGGTATGCAGg
gatccCAGGCGGATAGCGGA
agcttCCGCTATCCGCCTGg
gatccTGGGAACATGATGGa
agctTCCATCATGTTCCCAg
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Table 5: Primers for insertion into linker region of pGLO-Cath B Targets
Sequence
pGLBID
pGLBIN
pGLBNDP
pGLOST
pGLBTG
pGLPPCB
pGLREN

Primers 5' to 3' Fwd and Rev
gatccGCGAGCCGCAGCTTTAACCAGGGA
agctTCCCTGGTTAAAGCTGCGGCTCGCG
gatccGGCTTTGGCTTTGTGGGA
agctTCCCACAAAGCCAAAGCCG
gatccGGCTTTCTGCGCCGCATTCGCCCA
agctTGGGCGAATGCGGCGCAGAAAGCCG
gatccGCGTATCGCCGCTTTTATGGCCCA
agctTGGGCCATAAAAGCGGCGATACGCG
gatccCCGACCGTGGGCAGCTTTGGCTTTGGA
agctTCCAAAGCCAAAGCTGCCCACGGTCGGG
gatccTATCTGAAACGCCTGTGCGGCACA
agctTGTGCCGCACAGGCGTTTCAGATAG
gatccCCGATGAAACGCCTGACCCTGGGA
agctTCCCAGGGTCAGGCGTTTCATCGGG

33
pLVX Lentiviral Vector
The best performing constructs (pGLC7C1 and pGL18) were selected to have the
open reading frame (ORF) cloned into a lentiviral vector construct (pLVX). The
pGLLVX primers in Table 6 were designed to PCR amplify the gene of interest while
inserting an Xho1 restriction site 5’ and EcoR1 restriction site 3’ immediately flanking
the ORF of the pGLC7C1 or pGL18 gene. The pLVX construct was restriction digested
overnight with Xho1 and EcoR1 restriction enzymes in NEB buffer 3.1 both purchased
from (New England Biolabs ® Inc.) The amplified pGL18 and pGLC7C1 genes were
ligated into the Multiple Cloning Site of the double digested pLVX plasmid construct
using a Quick Ligation™ Kit (New England Biolabs ® Inc). Upon sequence verification
the pLVX18 and pLVXC7 were transfected into HEK293T cells along with helper
plasmids encoding VSVg and Capsid overnight. Media was changed on Day 1. On day
2 and day 3, supernatant was harvested, and filtered using a .45 micron filter.
Supernatant containing pLVX viral vector (pLVX18 or pLVXC7C1) was stored at
-80° C.
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Table 6: Primers used for PCR amplification of pGLO gene
Sequence
pGLLVX
pGLAAV
pGLCAG

Primers 5' to 3' Fwd and Rev
ggccgCTCGAGcgccatgccgggatcaac
cggccGAATTCttaaacacctttcggtgt
ggccgGAATTCcgccatgccgggatcaac
cggccCTCGAGttaaacacctttcggtgt
ggccgGAATTCcgccatgccgggatcaac
cggccCTCGAGttaaacacctttcggtgt

pGLAAV and pGLCAG Viral Vector
Of the best performing constructs (pGLC7C1, pGL18, and pGLWEHD),
pGLC7C1 was selected to have the open reading frame of the pGLO protein cloned into
an AAV vector construct (pGLAAV) and CAG promoter construct (pGLCAG). The
pAAV and pGLCAG primers were designed to PCR amplify the ORF of our gene of
interest while inserting an EcoR1 restriction site 5’ and Xho1 restriction site 3’ of the
gene. The pGLAAV and pGLCAG constructs were restriction digested overnight with
EcoR1 and Xho1 restriction enzymes in NEB buffer 3.1 both purchased from (New
England Biolabs® Inc.) The amplified pGL18 and pGLC7C1 genes were ligated into
the MCS of the pGLAAV and pGLCAG plasmids using a Quick Ligation™ Kit (New
England Biolabs® Inc.). Upon sequence verification the pGLAAVC7, pGLCAGC7,
pGLCAG18 and pCAGWE were stored at -20° C.
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PEI Transfection
HEK293T cells were plated at ~70 percent confluence in 100 microliters (µl) of
DMEM per well of a 96 well black wall, clear bottom plate (Corning® Inc). Cells were
allowed to adhere to the wells for 3 hours. In 41.5 µl of oxidized DMEM 225 nanograms
(ng) of a pGLO sensor construct for each of the target sequences in Table 1 with 75 ng of
a construct expressing ASC and 75 ng of a construct expressing Pro-Caspase-1 were
allowed to equilibrate for 5 minutes. Oxidized DMEM is prepared by leaving regular
DMEM as described previously overnight at room temperature on a shaker for ~5 days.
1 µl of vortexed polyethylenimine (PEI) was added to each 41.5 µl tube and allowed to
form liposome complexes for 10 minutes. 13 µl of each 41.5 µl pGLO sensor
transfection tube was dropped onto 1 well of a 96 well plate in triplicate. Cells were
incubated with PEI transfection complexes overnight for 14 hours and withdrawn the
next day. Media was replaced with CO2 independent media supplemented with 10% FBS
(Life Technologies) only and allowed to equilibrate for 2 hours prior to addition of
GloSensor® reagent (GLOS) (Promega®).

Lipofectamine 2000 Transfection
HeLa cells were plated in the afternoon at ~70 percent confluence in 100 µl of
DMEM per well of a 96 well black wall, clear bottom plate (Corning®) Cells were
allowed to adhere to the wells for 3 hours. Transient transfection was performed
according to the manufacturers protocol (Invitrogen®) with a final volume of .3 µl
Lipofectamine 2000 reagent and 100 ng of DNA per well. Experiments were performed
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in triplicate. Cells were incubated with transfection complexes overnight for 14 hours
and withdrawn the next day. Media was replaced with CO2 independent media
supplemented with 10% FBS only, and allowed to equilibrate for 2 hours prior to
addition of GloSensor reagent (GLOS).

Luminometer Readings
GloSensor reagent (GLOS) lyophilized powder was reconstituted as per the
manufacturer’s protocol in 10mM HEPES at a pH of 7.5. 2 µl of GLOS was added
directly to 100 µl of CO2 independent media in each well of a 96 well plate and allowed
to equilibrate for 2 hours. Readings were taken in a GloMax®-96 Microplate
Luminometer (Promega) every hour for 3-5 hours. Luminometer settings were as follows
for all reported experimental data collection: No injection, 1 Run, No Delay between runs
with an integration time of 1 second.

CHAPTER THREE
RESULTS

Generation of Candidate Inflammasome, Caspase-1 Sensors – Molecular Cloning
The pGloSensor-30F (pGLO) plasmid construct encodes a circularly permuted
Firefly Luciferase (cpLUC) with an unstructured linker region between N and C terminal
domains (Figure 9.) This linker region is unstructured and has been modified by
Promega® Corporation to contain two restriction sites, BamHI and HindIII. The
restriction sites are unique to the construct such that digestion of both sites will yield a
region where a short DNA sequence can be ligated. DNA encoding six separate amino
acid sequences recognized and cleaved by Caspase-1 was ligated into the pGLO (Table
7). Data shown in Figures 11-16 are diagnostic restriction digests to verify that the
candidate linker sequence has been inserted into pGLO. Double digesting the unique
linker region would yield an small approximately 20 base pair fragment unable to be
resolved on a standard agarose gel. We identified two SnaB1 sites and one Hind3 site
which upon overnight double digest with each enzyme would yield bands of
approximately 3997, 2702, and 1178 base pairs in length. The 3 predicted fragments can
be seen in Figure 10. Clones that upon double digestion with SnaB1 and Hind3 had
bands matching those of Figure 10 were sent for sequencing.
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Upon correct Sanger sequencing verification; the screen for the best performing Caspase1 sensor could be performed. Refer to Table 4-5 in Materials and Methods for DNA
sequence insertions for Figures 11-16.

Figure 9: pGloSensor-30F construct
Image provided courtesy of SnapGene, www.snapgene.com
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pGloSensor-30F DEVDG.gbk
Size
site1
site2
3997
HindIII
2707 SnaBI
2702
SnaBI
6704 SnaBI
1172
SnaBI
1535 HindIII

6704
1535
2707

Mass %
51
34
15
1535 SnaBI
2707 HindIII

6704 SnaBI

Figure 10: Predicted DNA bands from diagnostic restriction digest of clones
generated in Figure 11-16:
Image is obtained from the software program ApE – A Plasmid Editor by M.
Wayne Davis. Simulated DNA gel on the right indicates the size of bands
one would expect upon restriction digest of the pGLO vector with SnaB1
and HindIII with a properly inserted linker region. The proceeding figures
are evidence of successful cloning as per the lanes indicated by a star which
match the predicted lane in the above figure.

Figure 11: pGL18 diagnostic restriction digest
Lanes 1-5 pGL18 individual clones
Lanes marked with a star indicate a positive clone as verified by diagnostic
digest by SnaB1 and HindIII matching predicted bands in Figure 10 as well
as Sanger Sequencing verificatio
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Figure 12: pGLC7C1 and pGLPA diagnostic restriction digest
Lanes 1-5 pGLC7C1 individual clones, Lanes 6-9 pGLPA clones
Lanes marked with a star indicate a positive clone as verified by diagnostic
digest by SnaB1 and HindIII matching predicted bands in Figure 10 as well
as Sanger Sequencing verification

Figure 13: pGLIL1β diagnostic restriction digest
Lanes 1-5 pGLIL1β individual clones
Lanes marked with a star indicate a positive clone as verified by diagnostic
digest by SnaB1 and HindIII matching predicted bands in Figure 10 as well
as Sanger Sequencing verification
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Figure 14: pGC75, pIL1β5 diagnostic restriction digest
Lanes 1-4 pGLC75 individual clones, Lanes 6-14 pGLIL1β5 individual clones
Lanes marked with a star indicate a positive clone as verified by diagnostic
digest by SnaB1 and HindIII matching predicted bands in Figure 10 as well
as Sanger Sequencing verification
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Generation of Candidate Cathepsin B Sensors – Molecular Cloning
DNA encoding six separate amino acid sequences recognized and cleaved by
Cathepsin B were ligated into pGLO. As per the generation of the Caspase-1 sensors,
two SnaB1 sites and one Hind3 site were identified which upon overnight double
digestion with each enzyme would yield bands of approximately 3997, 2702, and 1178
base pairs in length. The 3 predicted fragments can be seen in Figure 15-16. The data
shown in Figure 15-16 is diagnostic restriction digest to verify that the candidate linker
sequence has been inserted into the pGLO

Figure 15: pGLOST, pGLPPCB, pGLBTG, pGLBNDP, diagnostic restriction
digest
Lanes 1-4 pGLOST, 5-8 pGLPPCB, 9-11 pGLBTG, 12-14 pGLBNDP individual
clones
Lanes marked with a star indicate a positive clone as verified by diagnostic
digest by SnaB1 and HindIII matching predicted bands in Figure 10 as well
as Sanger Sequencing verification
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Figure 16: pGLBID, pGLBIN, pGLREN, diagnostic restriction digest
Lanes 1-4 pGLBID, 5-7, 9 pGLBIN, 10-13 pGLREN individual clones
Lanes marked with a star indicate a positive clone as verified by diagnostic
digest by SnaB1 and HindIII matching predicted bands in Figure 10 as well
as Sanger Sequencing verification
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Detection of Inflammasome Activation in Live Cells
The pGloSensor™ (pGLO) construct encodes a luciferase protein (cpLUC) from
Photuris pensylvanica with a similar catalytic mechanism to commonly utilized firefly,
Photinus pyralis luciferase. cpLUC has been circularly permuted at residue 358 such that
amino acid residues 358-544 are now positioned towards the N-Terminus and 4-354 are
at the C-Terminus with an unstructured Gly-Ser linker region in between. (Figure 8) It
has been demonstrated that by inserting in certain consensus cleavage sequences targeted
by specific proteases one can observe statistically significant increases in luminescence
upon activation of the respective protease. The pGLO construct we began our studies
with has been optimized for detecting Caspase 3/7 activity through cleavage of a 5 amino
acid DEVDG linker region. pGLDEVD has undergone a high throughput screen (HTS)
of over 21,648 possible mutations for the best performing construct [27]. The optimized
pGLDEVD for detection of Caspase 3/7 activation has a Threonine to Isoleucine point
mutation at amino acid 151 as compared to the pGloSensor22F construct available
commercially through Promega®.
There are a small number of publications utilizing the generalized pGLO
construct to measure protease activity for proteins such as: Granzyme B, Caspase 3/7,
and MERS CoV papain like protease. We initially choose to screen four 8 amino acid
sequences from the proteins IL1β, IL18, Parkin1, and Caspase 7 [85-88]. To probe for
the sensitivity of the constructs designed for our screen we transiently transfected
HEK293T cells with a plasmid encoding one construct from: pGLIL1β, pGL18, pGLPA,
and pGLC7C1. To activate the Inflammasome in a non-myeloid cell line presumed to

45
not exhibit capabilities for induction of robust Caspase-1 activity; we co-transfected two
of the three components of the NLRP3 Inflammasome, ASC and Pro-Caspase 1.
HEK293T cells were transfected, in triplicate, overnight and luminescence
measured 14 hours post transfection in a 96 well plate (Figure 17). Each experimental
well (XP) of a 96 well plate received 75ng pGLO candidate sensor, 25ng ASC, and 25ng
Pro1. The control wells (CTRL) substituted ASC and Pro1 for 50 ng of GFP. To our
surprise, pGLC7C1 cleavage resulted in the highest levels of luminescence in both raw
RLU as well as fold induction versus GFP control as seen in (Figure 18). Our initial
hypothesis favored pGLIL1 β, containing a cleavage sequence recognized by the
literature as belonging to the canonical output of inflammasome activation as the frontrunner for the candidacy as the most robust inflammasome sensor.
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Figure 17: Generalized Experimental Schematic
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Table 7: Peptide linker region targets of Caspse-1
Sequence
pGLC7C1

Peptide Linker
IQAD-SGPIG

Reference
86,89

pGLIL1β

YVHD-APVRG

87

pGL18

LESD-YFGKG

88

pGLPA

LHTD-SRKDG

85

pGLC75

QAD-SG

86,89

pGLWEHD

WEHD-G

70
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Figure 18: Transient Transfection screen of 4 Caspase 1 target constructs
(A) Luminometer data from PEI transfection of HEK293T cells at various time points
post GloSensor (GLOS) incubation. Each control wells (CTRL) received 75ng
pGLO candidate sensor, 50ng GFP. Each experimental wells (XP) received 75ng
pGLO candidate sensor, 25ng ASC, 25ng Pro-Caspase-1. Data represent the mean
and standard deviation of 3 replicates.
(B) Fold induction luminescence of experimental well versus control. Values are
calculated by dividing pGLO candidate XP value by pGLO candidate CTRL
value at each indicated time point. Data represent the mean of 3 replicates.
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Fold Induction Inflammasome Activation
To standardize for the various types of luminometers (LUM) commercially
available, luminescence data is typically presented as fold induction versus
control.(Figure 18) The numerator in the calculation for fold induction is the raw value
in RLU for a given candidate sensor construct with co-transfection of ASC and ProCaspase-1. The denominator in the calculation is the raw value in RLU for a given
candidate sensor construct with co-transfection of equalized volume of GFP.

Linker Optimization and Characterization
cpLUC has undergone molecular changes especially in its DNA sequence but also
to a lesser degree in its overall tertiary and quaternary structure. The catalytic activity of
the protein is indeed intact, however, it is a hypo-functional enzyme compared to wild
type FFL. As the success of the original Caspase 3/7 sensor, pGLDEVD involved a 5
amino acid linker region instead of 8; we hypothesized that reducing the length of the
linker region in our most robust sensor may increase the sensitivity. We removed 4
amino acids, from a linker region which was previously 8 amino acids in the construct
generating the highest levels of luminescence. We performed the same experimental
paradigm as in Figure 17 by co-expressing ASC and Pro-Caspase-1 together with one of
two candidate sensors in HEK293T cells. The data suggest that in our screen for Caspase
1 cleavage sequences, an 8 amino acid target sequence is ideal versus a truncated form of
the same sequence.
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Figure 19: Transient Transfection Screen of 5AA mutants
Luminometer data from PEI transfection of HEK293T cells. Each control wells
(C7CTRL or C75AACTRL) received 75ng pGLO candidate sensor pGLC7C1 or
pGLC7C5, 50ng GFP. Each experimental wells (XP) received 75ng pGLO candidate
sensor (pGLC7C1 or pGLC7C5), 25 ng ASC, 25 ng Pro-Caspase-1. Data represent the
mean and standard deviation of 3 replicates. Data collection began 3 hours post
GloSensor (GLOS) incubation.

Caspase-1 Consensus Sequence and pGLDEVD Specificity Probe
Upon recognizing the magnitude of an approximately ~350 fold increase in
luminescence utilizing the pGLC7C1 construct from Figure 18, we questioned the
specificity of our sensor. The short 8 amino acid sequence IQAD-SGPI present in the
best performing pGLC7C1 sensor is normally present in between the p20 and p10
subunits of Pro-Caspase-7. IQAD-SGPI is known to be targeted by both Caspase-8 and 9
[89]. However, Caspase-substrate interactions are thought to also be mediated by
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unidentified exosite- or protein-protein interactions between sites distal to the known
region of contact or cleavage [25] [86]. This phenomenon is alleged to explain the
discrepancies observed between experimentally observed in vitro Caspase substrates
versus in vivo substrates [25]. The crosstalk between pyroptosis and apoptosis has been
documented, and our findings are intriguing in light of these facts. However, our
objective is to create a sensor specific for Caspase-1. Thus, we pursued further
experiments to generate an alternative candidate sensor construct based on a well
published WEHD Caspase-1 consensus cleavage sequence [71]. Figure 20 demonstrates
that we have found an alternative candidate Caspase-1 sensor in the form of a 5 amino
acid WEHD insertion of a consensus sequence identified in proteomics screens.
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Figure 20: Transient Transfection screen of additional Caspase 1 target
constructs presented as fold induction over control values.
Fold induction luminescence of experimental wells versus control. Values are calculated
by dividing pGLO candidate XP value by pGLO candidate CTRL value at each indicated
time point. Data represent the mean of 3 replicates
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Generation of pLVX Vector – Molecular Cloning
Next, we probed the sensitivity of our sensor by generating two HeLa stable cell
lines with a single insertion of the open reading frame encoded by pGLC7C1 and
pGLIL18. To create our lentivial vector we first needed to insert Xho1 and EcoR1
restriction sites flanking the ORF of the pGLC7C1 and pGLIL18 gene as described in the
Materials and Methods. We double digested the MCS and the PCR amplified sensor
genes themselves with Xho1 and EcoR1 respectively. The middle band shown in Figure
21-22 corresponds to the pGLC7C1 or pGLIL18 ORF sensor gene pLVX insertion.

Figure 21: pLVXC7C1 diagnostic restriction digest
Lanes marked with a star indicate a clone positive for insertion of the pGLO
ORF as verified by diagnostic digest by via Xho1 and EcoR1. The middle
band of each lane is the predicted size for the pGLO ORF.
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Figure 22: pLVXIL18 diagnostic restriction digest
Lanes marked with a star indicate a clone positive for insertion of the pGLO
ORF as verified by diagnostic digest by via Xho1 and EcoR1. The middle
band of each lane is the predicted size for the pGLO ORF.

Inflammasome activation in HeLa stable cell line
We generated a stable cell line, HeLa C7C1 incorporating a lentiviral insertion of
our pGLC7C1 gene. Although HeLa cells are not of the myeloid lineage, we were able to
induce Inflammasome activation through a Lipofectamine 2000 transfection of ASC and
Pro-Caspase-1.
HeLa C7C1 cells were transfected, in triplicate, overnight and luminescence
measured 14 hours post transfection in a 96 well plate. All wells were treated with
GloSensor one hour before taking readings. The first group HeLa C7C1 alone (-)
consisted of HeLa C7C1 cells treated with GloSensor only. Each control well of the
group HeLa C7C1 + GFP (Figure 23) received 100ng GFP and .3 ul Lipofectamine
2000. Each experimental well of the group Hela C7C1 + ASC/Pro1 (Figure 23)
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received 50ng GFP, 25ng ASC, and 25 ng Pro-1. Time is in Hours post GloSensor
(GLOS) incubation.
One can see in Figure 23, B that the transfection itself did not contribute to
inflammasome activation. Thus all of the signal must be due to our overexpression
paradigm. Fold enhancement luminescence ranged from ~14-20, a statistically
significant outcome. This data shows that genomic insertion and expression of one copy
of pGLC7C1 is sufficient to measure inflammasome activation in our NLRP3 over
expression system. Next we set out to place pGLC7C1 under control of a stronger
promoter which could then be utilized to generate a different viral vector suitable for
creation of an in vivo animal model
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Figure 23: HeLa stable cell line Lipofectamine 2000 transfection
(A) Luminometer data from Lipofectamine 2000 transfection of HeLa cells. Each
respective bar indicate data gathered 1 hour (Time 1), 2 hours (Time 2), or 3
hours (Time 3) post GloSensor incubation. Data represent the mean and standard
deviation of 3 replicates.
(B) Fold induction luminescence of experimental well versus control. Values are
calculated by dividing pGLO candidate XP value by pGLO candidate CTRL
value at each indicated time point. Data represent the mean of 3 replicates.
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Generation of pGLAAV-C7C1
Following the success of the HeLa C7C1 stable cell line experiment the next goal
is creation of an in vivo animal model. We set forth to make an Adeno-Associated-Virus
(AAV) more commonly known in the realm of gene therapy. AAV’s form
extrachromosomal concatamers inside the cells they infect which will stably express a
gene of interest [90]. While we did not choose to move forward with utilizing the
pGLAAV-MCS with the pGLC7C1 gene insertion, the evidence for successful cloning
can be seen in Figure 24. The AAV-MCS promoter uniquely contains a β -globin intron
element between the CMV promoter and MCS. Thus we utilized our HEK293T
overexpression system to achieve ~43,000 RLU at a 1 and 2 hour time point with a
pGLAAV-C7C1 plasmid. (data not shown)

Figure 24: pGLAAV -C7C1 diagnostic restriction digest
Lanes marked with a star indicate a clone positive for insertion of the pGLO
ORF as verified by diagnostic digest by via EcoR1 and Xho1. The middle
band of each lane is the predicted size for the pGLO ORF.
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Generation of pCAGC7C1, pCAG18, pCAGWE
Upon observing the large increase in luminescence with our pGLC7 sensor under
control of an AAV promoter in the pAAV-MCS-C7C1 construct, we set out to place our
gene under control of a different promoter. The synthetic CAG promoter consists of the
CMV early enhancer, the promoter and part of the gene encoding chicken- β -actin, as
well as the rabbit- β globin hybrid promoter.

The CAG enhancer-promoter element can

be utilized to drive very high levels of constitutive gene expression in mammals. We
utilized our HEK293T overexpression system to achieve ~50,000 RLU with our
pGLC7C1 sensor gene inserted into the pCAG-MCS (Multip (data not shown). We
have cloned the pGLIL18, and pGLWEHD ORF into the pCAG-MCS in order to create
additional transgenic mice. We hypothesize that a stable insertion of multiple copies of
the pCAGC7, pCAG18, or pCAGWEHD into all of the cells of a transgenic mouse will
lead to an in vivo animal model capable of detecting Caspse-1 activity in real time.

Figure 25: pCAGC7C1 diagnostic restriction digest
Lanes marked with a star indicate a clone positive for insertion of the pGLO
ORF as verified by diagnostic digest by via EcoR1 and Xho1. The middle
band of each lane is the predicted size for the pGLO ORF.
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Figure 26: pCAG-IL18 diagnostic restriction digest
Lanes marked with a star indicate a clone positive for insertion of the pGLO
ORF as verified by diagnostic digest by via EcoR1 and Xho1. The middle
band of each lane is the predicted size for the pGLO ORF.

Figure 27: pCAG-WEHD diagnostic restriction digest
Lanes marked with a star indicate a clone positive for insertion of the pGLO
ORF as verified by diagnostic digest by via EcoR1 and Xho1. The middle
band of each lane is the predicted size for the pGLO ORF.

CHAPTER FOUR
DISCUSSION
The ability to quantify inflammasome activation both in vitro and in vivo with a
large dynamic range and lack of significant background interference is a necessary
advance to drive development of new therapeutics. The assay we have developed is not
without flaws to be worked out before the potential for widespread use is realized. Our
pGLO based Caspase-1 sensors must be shown to exhibit a statistically significant
increase in luminescence in a myeloid cell line. Sensor activation must also be induced
by a physiologically relevant stimulus such as a DAMP or PAMP.
In this study, we utilized an overexpression system in HEK293T and HeLa cell
lines. We have transfected two out of three components of the NLRP3 inflammasome
and observed that overexpression of ASC and Pro-Caspase-1 leads to activation of a
panel of pGLO derived Caspase-1 protease sensors. The NLRP3 receptor is a known
component of the NLRP3 inflammasome; thus our overexpression system may not
achieve maximal inflammasome activation [31]. This is encouraging logic; leaving the
door open to the potential of the sensor in a physiologically relevant setting under control
of a highly active promoter. However, to counter this logic we performed an experiment
in which we overexpressed the NLRC4 inflammasome components (IPAF and ProCaspase-1) side by side with ASC and Pro-Caspase-1 which; lead to equivalent levels of
luminescence (RLU) in our pGLC7C1-HEK293T paradigm.
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Overexpression of Caspase-1 has been shown to induce apoptosis, a phenomenon which
we did not observe 24 hours post data collection [91].
We created a stable cell line through a pLVX vector mediated incorporation of the
pGLC7C1 ORF into a non-myeloid cell line (HeLa C7C1) and induced activation of our
pGLO inflammasome sensor through overexpression of ASC and Pro-Caspase-1. This
data in Figure 22, illustrate the approximately 20-fold maximal increase in luminescence
in response to overexpression of ASC and Pro-Caspase-1; NLRP3 inflammasome
components in this stable cell line. It can be seen that stable insertion of one copy of our
pGLC7C1 ORF via a pLVX Lentiviral vector in our HeLa C7C1 stable cell line results in
a much lower fold induction luminescence as well as absolute RLU values versus the
HEK293T transfection paradigm. This effect could also be due to decreased transfection
efficiency of ASC and Pro-Caspase-1 in the HeLa C7C1 cells versus HEK293T.
Variances in the stability of the inflammasome components in each cell line through
factors such as differential gene expression of regulatory components such as POP’s or
COP’s could play a role [41, 45].
We attempted to induce inflammasome activation in the HeLa C7C1 stable cell
line through a dose response treatment of the pore forming toxin, Nigericin. We
generated a BV2 C7C1 microglia stable cell line analogous to the HeLa C7C1 line. We
induced inflammasome activation via a dose response treatment of a pesticide, Rotenone.
These treatments failed to produce statistically significant luminescence output in our
HeLa C7C1 and BV2 C7C1 microglia stable cell lines. The lack of an effect in HeLa
cells may be attributed to lack of normal expression of inflammasome components.
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Microglial expression of inflammasome components is documented, but the relationship
between Neurological Disease and Inflammation is only beginning to be elucidated. [10,
35, 92]. One could speculate that a single insertion of the pGLC7C1 sensor gene through
infection via the pLVX lentiviral vector produced insufficient levels of pGLC7C1
protein.
Next, we infected primary human monocytes and macrophages with pLVX
lentiviral vector incorporating the pGLC7C1 ORF. We tested activation of the
Inflammasome in response to a physiologically relevant stimulus – supernatant
containing alpha-toxin from a strain of Methicillin-Resistant Staph aureus, MRSA
courtesy of Dr. Francis Alonzo [93]. These experiments failed to detect any significant
increase in luminescence in response to a known Inflammasome activator.
Maintaining physiological relevancy is important to elicit further investment in
this technology. The cloning of our pGLO sensor genes downstream of strong AAV or
CAG promoters will allow for increased luminescent output due to increased levels of
protein expression. Under the same experimental HEK293T transfection paradigm
exhibited in (Figure 16), we have shown an approximate 40000-50000 (RLU) output in
luminescence (RLU) with the pGLC7C1 ORF under control of an AAV or CAG
synthetic promoter. It remains to be determined if a pGLO inflammasome sensor under
control of the CAG or AAV promoter will elicit statistically significant increase in
luminescence in response to a physiologically relevant stimulus in vivo or in an isolated
primary cell culture system.
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The specificity of the sensor is at the crux of the future utility of this assay. The
best performing pGLO sensor, pGLC7C1 utilized the 8 amino acid sequence insertion
belonging to Pro-Caspase-7 [86, 89]. It is possible that pGLC7C1 could detect activation
of other Caspases, particularly Caspase-3/7. It is known that activation of an individual
Caspases is mediated specifically by one or more other individual Caspases or the
original Caspase itself. [21]. This possibility was addressed via cloning of the Caspase-1
consensus sequence WEHD into the pGLO vector. In our favor, Caspase 3 has a flap
over its active site, which is absent in Caspase-1 perhaps suggesting the exclusion of
certain substrates such as bulky amino acids like tryptophan, W [94, 95]. These
produced similar levels of luminescence in our HEK293T paradigm illustrating two
inflammasome sensors with the same sensitivity but perhaps differing specificities. A
potential problem with this sensor is an overlap in P4 site specificities amongst all of the
Group 1 Inflammatory Caspases. pGLWEHD may be sensitive to Caspase 1 as well as 4
and 5 and thus may prove to be a Group 1 Inflammatory Caspase sensor. If future
experiments elicit a signal in response to a physiologically relevant stimulus then one
would certainly want to inhibit Caspase 4, or 5, or both to test for the sensors specificity.
We have conclusively added Caspase-1 to the list of proteases able to be
monitored via modifications to a Promega ® developed circularly permuted Firefly
Luciferase (cpLUC). While the data documented in this thesis is encouraging, the fact of
the matter is that a German group has developed an inflammasome Assay (iGLUC) based
on the aforementioned Gaussia luciferase which catalyzes raw luminescence signals far
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brighter than those capable with Firefly Luciferase [96]. Gaussia luciferase marketed by
Promega® as Nano-Luc is fast becoming the alternative to Firefly Luciferase.
The potential to generate a stable cell line for High-Throughput-Screening of
candidate therapeutics for the myriad diseases continually being found to have a
component of inflammasome activity still exists. The recent Q3 release of the Promega
Caspase-Glo® 1 inflammasome Assay presents an alternative to our assay if we choose
to pivot towards a HTS approach. Promega® product supporting data indicates that the
Caspase-Glo® 1 assay can reach ~22,000 RLU in treated Pam3CSK4 cells in addition to
the ability to monitor Caspase-1 activity in the culture medium. However, a poor signal
to noise ratio of 12.40 in culture media or 4.63 in Pam3CSK4 cells indicate the lack of a
broad dynamic range. A final test of the utility of pGLO in serving as a sensor of the
inflammasome in an HTS setting would surely involve lentiviral or other viral mediated
stable insertion of a pGLO sensor gene under control of the highly active CAG promoter.
This could present an inexpensive alternative to the Caspase-Glo® 1 assay as one can use
the Luciferin reagents from the Dual-Luciferase assay for a lytic end-point assay as an
alternative to the cAMP gloSensor (GLOS) reagent mediated ability to take readings over
the course of hours. Prior to performing this test it would be important to perform
another HTS screen through error-prone-PCR or one of many various mutagenic methods
to generate the sensor with the best possible catalytic activity.
The scientific impact of the successful directed evolution of a natural protein to
serve as a sensor for myriad proteases by Promega®, in live cells over time is substantial
[27]. The utility in the pGLO system is in the ability to sense a protease possessing an
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exposed active site, like the Caspase family, with little dependence on exosites for their
catalytic activity [25]. The data documented in this thesis should not discourage one from
pursuing development of a custom protease sensor for a protease of interest via the pGLO
system [9, 19, 23, 27, 84]. Caspase-1 is known to be quickly and transiently activated;
followed by rapid deactivation in a wild-type scenario as opposed to apoptotic Caspase
3/7 [97]. The existence of databases such as CutDB (cutdb.burnham.org) - which
extensively document proteases and their cleavage sites sets the stage for a new
generation of sensors which depart from the more conservative, highly cited consensus
cleavage sequences like DEVD, or WEHD, and into natural substrates such as IQADSGPI present in the Caspase 7 zymogen.
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